



**CYTEC INDUSTRIES INC.**

Legal and Compliance Services  
Five Garret Mountain Plaza  
Woodland Park, NJ 07424

Transmitted via the Chemical Information Submission System (CISS)

April 8, 2015

TSCA Confidential Business Information Center (7407M)  
EPA East - Room 6428 Attn: Section 8(e)  
U.S. Environmental Protection Agency  
1201 Constitution Avenue, NW  
Washington, DC 20004-3302

**PUBLIC COPY  
DOES NOT CONTAIN  
CONFIDENTIAL BUSINESS  
INFORMATION**

Dear Sir/Madam:

Pursuant to the requirements of TSCA § 8(e), Cytec Industries Inc. ("Cytec") is submitting the preliminary results obtained from a study performed on a substance identified by Chemical Abstracts Service Registry Number ("CASRN") 78-50-2 which is described by the chemical name Tri-N-Octylphosphine Oxide. The test performed on the substance that is the subject of Cytec's TSCA § 8(e) submission is a Combined 28-Day Repeated Dose Toxicity Study with a Reproduction/Developmental Toxicity Screen (OECD 422).

A summary of the preliminary adverse findings, after the in-life portion of the study concluded, is as follows:


- Study was conducted via oral gavage at dose levels of 100, 300 and 1000 mg/kg/day
  - Repeat Dose Portion of the Study
    - At high dose 1000 mg/kg/day – effects seen in biochemistry parameters and organ weights
    - Liver weights increased in females across all dose levels
  - Reproductive/Developmental Screen Portion of the Study
    - At high dose 1000 mg/kg/day
      - Seeing trend (not statistically significant) for lower values for number of implantation sites and number of corpora lutea
      - Increased number of post natal pup deaths and also lower pup body weights – both are statistically significant over control values

Histopathology is currently in progress and is expected to be completed and a draft report issued by the end of June. At that time, we will have more conclusive data in terms of NOAEL for systemic effects and also be able to determine the potential for this substance to produce developmental/reproductive effects. Upon receipt and review of the draft report we will provide an update.

Cytec does not consider any of the information provided herein to be TSCA Confidential Business Information ("TSCA CBI"). Please direct all communications regarding Cytec's TSCA § 8(e) submission to

Ms. Patricia Vernon, Senior Manager, Global Product Regulatory Compliance at the address above or call her at (973) 357-3375.

Sincerely,



Jeffrey H. Koenig  
Chief Litigation Counsel & Compliance Officer  
Cytec Industries Inc.

Cc: P. Vernon, Cytec  
A. Essinfeld, Cytec  
T. McColl, Cytec

**PUBLIC COPY  
DOES NOT CONTAIN  
CONFIDENTIAL BUSINESS  
INFORMATION**